Various tumor types overexpress CD47 [16, 17, 18], enabling evasion of macrophage‐mediated phagocytosis [17], making the SIRPα‐CD47 interaction an attractive therapeutic target [19]. The gene discussed is SIRPA; the disease is neoplasm.